MAPT and Alzheimer disease: Recent work has shown that a commercially available p-tau217 assay had accuracy comparable to CSF biomarkers in predicted Alzheimer’s dementia neuropathology in cohorts both with and without cognitive impairment, and also outperformed other p-tau isotopes.12 The relative ease of blood sampling would also allow for deployment of testing at scale, thereby improving accessibility and facilitating earlier diagnosis.